Molecure SA
WSE:MOC
Molecure SA
Revenue
Molecure SA
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
Molecure SA
WSE:MOC
|
Revenue
zł1.3m
|
CAGR 3-Years
-78%
|
CAGR 5-Years
237%
|
CAGR 10-Years
N/A
|
|
|
C
|
Celon Pharma SA
WSE:CLN
|
Revenue
zł280.8m
|
CAGR 3-Years
15%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
C
|
Cannabis Poland SA
WSE:CBD
|
Revenue
zł54.6k
|
CAGR 3-Years
11%
|
CAGR 5-Years
40%
|
CAGR 10-Years
N/A
|
|
Molecure SA
Glance View
Molecure SA engages in the discovery and development of small molecules for the treatment of unmet medical needs. The company is headquartered in Warsaw, Woj. Mazowieckie and currently employs 106 full-time employees. The company went IPO on 2018-04-19. The firm is dedicated to discovering, developing and commercializing therapeutics for neoplastic and inflammatory diseases. The firm's business model is focused on drug discovery and development, with its core strength in medicinal chemistry and preclinical biology, enhanced by scientific collaborations in specific disease areas. The firm has a platform of 3 distinct small molecule programs targeting chitinases hydrolytic enzymes with potential utility in diverse inflammatory and fibrotic diseases of high unmet medical need. Additionally, it has initiated a program focused on development of small molecule immune modulators to stop the ability of tumors to escape immune surveillance.
See Also
What is Molecure SA's Revenue?
Revenue
1.3m
PLN
Based on the financial report for Dec 31, 2023, Molecure SA's Revenue amounts to 1.3m PLN.
What is Molecure SA's Revenue growth rate?
Revenue CAGR 5Y
237%
Over the last year, the Revenue growth was -19%. The average annual Revenue growth rates for Molecure SA have been -78% over the past three years , 237% over the past five years .
You don't have any saved screeners yet